Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesLipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09
Robinson JG et al. – Ezetimibe/simvastatin (E/S) is more likely to result in lipid treatment endpoints than atorvastatin and was generally well tolerated at the compared doses.
Methods- Double-blind, randomized, 6-week study of lipid-lowering efficacy of E/S 10/20 mg vs atorvastatin 10 or 20 mg, and E/S 10/40 mg vs atorvastatin 40 mg
- Subjects: 1,128 pts with hypercholesterolemia and the metabolic syndrome
- Primary endpoint: percentage of change from baseline in low-density lipoprotein (LDL) cholesterol
- Additional endpoints: changes in other lipids, lipoprotein ratios, high-sensitivity C-reactive protein, and attainment of pre-specified lipid levels
- Significantly greater improvements in levels of LDL cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios with E/S vs atorvastatin at all dose comparisons
- Attainment of prespecified LDL cholesterol and non–high-density lipoprotein cholesterol levels significantly greater with E/S vs atorvastatin at all dose comparisons
- High-density lipoprotein cholesterol increases significantly greater with E/S 10/20 mg vs atorvastatin 10 mg and E/S 10/40 mg vs atorvastatin 40 mg
- Changes in triglycerides, very low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein similar for both treatments
- Low incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events, generally similar to those in previous studies of E/S and/or atorvastatin
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: Results of the ICARIA study
Atherosclerosis, 12/04/09
Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case–control study
Atherosclerosis, 12/04/09
Endothelial activation, inflammation and premature atherosclerosis in children with familial dyslipidemia
Atherosclerosis, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor